What are the indications for intravenous meropenem 1 g administered twice daily?

Indications for Intravenous Meropenem 1 gm BD

Meropenem 1 gram twice daily (every 12 hours) is NOT the standard FDA-approved dosing regimen and should generally be avoided. The FDA-approved dosing is 1 gram every 8 hours for most indications 1.

FDA-Approved Indications (Standard Dosing: 1g q8h)

Based on the FDA label, meropenem is indicated for 1:

1. Complicated Intra-Abdominal Infections

• Standard dose: 1 gram IV every 8 hours
• Duration: 5-10 days 2
• Caused by susceptible organisms including E. coli, K. pneumoniae, P. aeruginosa, Bacteroides fragilis, and others

2. Complicated Skin and Skin Structure Infections

• Standard dose: 500 mg IV every 8 hours (or 1g q8h for P. aeruginosa) 1
• Duration: 7-14 days depending on severity 2

3. Bacterial Meningitis (Pediatric ≥3 months only)

• Pediatric dose: 40 mg/kg (max 2g) every 8 hours 1
• Caused by H. influenzae, N. meningitidis, and penicillin-susceptible S. pneumoniae

When 1g BD (Every 12 Hours) May Be Appropriate

The only scenario where meropenem 1g every 12 hours is recommended:

Renal Impairment

• Creatinine clearance 26-50 mL/min: 1 gram every 12 hours 1
• Creatinine clearance 10-25 mL/min: 500 mg every 12 hours 1
• Creatinine clearance <10 mL/min: 500 mg every 24 hours 1

Multidrug-Resistant Organism (MDRO) Indications

For carbapenem-resistant Enterobacterales (CRE), meropenem is used in combination therapy with extended infusion 2:

CRE Bloodstream Infections

• Meropenem 1g IV q8h by extended infusion (3 hours) + colistin or tigecycline 2
• Duration: 7-14 days 2
• Note: Extended infusion is critical when MIC ≥8 mg/L 2

CRE Complicated Intra-Abdominal Infections

• Meropenem 1g IV q8h by extended infusion + colistin or tigecycline 2
• Duration: 5-7 days 2

Hospital-Acquired/Ventilator-Associated Pneumonia

• Meropenem 1g IV q8h for P. aeruginosa or Enterobacterales 3
• Duration: 10-14 days 2
• For MDRO risk: Consider combination with aminoglycoside or fluoroquinolone 3

Critical Dosing Considerations

Extended Infusion is Superior in Critical Illness

• Standard bolus (5-30 min) vs. extended infusion (3-6 hours) vs. continuous infusion
• Extended/continuous infusion achieves better PK/PD targets (100% fT>MIC or fT>4×MIC) 4, 5, 6
• For critically ill patients: 2g q8h by 3-hour infusion is optimal for MIC ≤2 mg/L 4
• For MIC 4-8 mg/L: Requires 2g q8h by 4-6 hour infusion or continuous infusion 5

Augmented Renal Clearance (ARC)

• Patients with CrCl 140-200 mL/min require higher doses 5
• Recommended: 2g q8h by 2-6 hour infusion for K. pneumoniae 5
• Standard dosing results in subtherapeutic levels 5

Continuous Renal Replacement Therapy (CRRT)

• Alternate-day PIRRT: 1g loading dose, then 500 mg q8h 7
• Daily PIRRT: 750-1000 mg q8h depending on session duration 7
• CVVH/CVVHDF: 1g q12h adequate for flow rates up to 3 L/hr 8

Common Pitfalls

1. Using 1g BD in normal renal function: This provides inadequate coverage and risks treatment failure
2. Ignoring MIC values: For MIC >2 mg/L, standard dosing is insufficient even with extended infusion 4, 5
3. Not using extended infusion in sepsis: Bolus dosing achieves target in only 67% of ICU patients 8
4. Overlooking ARC: Young trauma/burn patients may have CrCl >130 mL/min requiring dose escalation 5
5. Inadequate duration: Stopping at 5 days for bloodstream infections increases relapse risk 2

Drug Interactions

• Valproic acid: Meropenem reduces valproic acid levels by 50-100%, increasing seizure risk—add supplemental anticonvulsant 1
• Probenecid: Avoid co-administration (increases meropenem levels unpredictably) 1